Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes Aging & Longevity

Inside Equinox’s Elite $40,000 Longevity Program: What You Need to Know

by Team Lumida
May 17, 2024
in Aging & Longevity, Health and Longevity, Lifestyle, Themes
Reading Time: 3 mins read
A A
0
woman wearing black sports bra

Photo by Scott Webb on Pexels.com

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

  1. Equinox offers a $40,000 annual personalized wellness program.
  2. Program includes extensive lab tests, personal training, and wellness coaching.
  3. Focus on longevity aligns with global wellness trends.

What Happened?

Equinox introduced Optimize by Equinox, a personalized wellness program costing $40,000 per year. Launching in New York and Texas, the program aims to help members enhance their longevity and overall health. Members receive in-depth assessments, lab tests, personal training sessions, nutritional coaching, sleep coaching, and more.

The initiative is a partnership with Function Health, co-founded by Dr. Mark Hyman. Equinox’s program reflects a growing trend in the wellness industry, where high-end fitness centers evolve into comprehensive health and longevity clinics.

Why It Matters?

Why should you care about Equinox’s new program? The wellness industry is booming, and Equinox’s move to offer a $40,000 personalized program highlights the increasing demand for comprehensive health and longevity solutions. This shift could attract high-net-worth individuals seeking top-tier health services, potentially boosting Equinox’s revenue and market position.

Moreover, the partnership with Function Health underscores the value of integrating advanced medical diagnostics with fitness. This trend could drive innovation and competition in the wellness market, offering investors new opportunities.

What’s Next?

So, what’s next for Equinox and the wellness industry? Equinox plans to expand the program to more markets throughout the year, potentially increasing its membership and market share. As the demand for longevity and preventive health services grows, expect more fitness brands to adopt similar models.

Investors should watch for further developments in the wellness sector, particularly those involving partnerships with medical and diagnostic companies. Equinox’s success could signal a broader industry shift, emphasizing the importance of holistic health and personalized wellness programs in the future.

Previous Post

The Truth About Full-Body MRIs: A $2,500 Investment in Your Health?

Next Post

Xpeng Charges Into Hong Kong with New EV Models

Recommended For You

Waymo Hits 10 Million Rides, Leading the Driverless Revolution

by Team Lumida
22 hours ago
a car that is driving down the street

Key Takeaways: Powered by lumidawealth.com Waymo, Google’s autonomous taxi service, has surpassed 10 million paid rides, with exponential growth expected to reach 20 million by the end of 2025....

Read more

EssilorLuxottica Acquires AI-Driven Ophthalmology Platform Optegra to Expand Medical Technology Portfolio

by Team Lumida
2 days ago
EssilorLuxottica Acquires AI-Driven Ophthalmology Platform Optegra to Expand Medical Technology Portfolio

Key Takeaways: Powered by lumidawealth.com EssilorLuxottica, the maker of Ray-Ban, announced plans to acquire Optegra, an AI-focused ophthalmology platform operating over 70 eye hospitals across Europe. The acquisition aligns...

Read more

Microdosing Weight-Loss Drugs Like Ozempic Gains Popularity Despite Safety Concerns

by Team Lumida
3 days ago
Microdosing Weight-Loss Drugs Like Ozempic Gains Popularity Despite Safety Concerns

Key Takeaways: Powered by lumidawealth.com Some consumers are microdosing GLP-1 drugs like Ozempic, Wegovy, and Zepbound to save money, reduce side effects, or for perceived health benefits. A survey...

Read more

Delaware AG Seeks Investment Bank to Advise on OpenAI Restructuring Amid Legal and Regulatory Scrutiny

by Team Lumida
3 days ago
AI Security Breach: How Hackers Stole OpenAI’s Internal Secrets

Key Takeaways: Powered by lumidawealth.com Delaware Attorney General Kathy Jennings plans to hire an investment bank to advise on OpenAI’s restructuring and conduct an independent valuation of its assets....

Read more

Nvidia Posts Record $44 Billion Revenue Despite China Ban, Shares Surge Over 5%

by Team Lumida
3 days ago
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Key Takeaways: Powered by lumidawealth.com Nvidia’s Q1 revenue reached a record $44.06 billion, a 69% year-over-year increase, despite losing $2.5 billion in sales due to U.S. restrictions on chip...

Read more

We Made a Film With AI: Revolutionary Tools, Human Creativity, and a Lot of Work- WSJ

by Team Lumida
4 days ago
We Made a Film With AI: Revolutionary Tools, Human Creativity, and a Lot of Work- WSJ

Key Takeaways: Powered by lumidawealth.com Using AI tools like Google’s Veo 3 and Runway AI, WSJ producers created a three-minute film, “My Robot & Me,” entirely with AI-generated visuals...

Read more

Capgemini Partners with SAP and Mistral AI to Deliver Generative AI Solutions for Regulated Industries

by Team Lumida
5 days ago
Capgemini Partners with SAP and Mistral AI to Deliver Generative AI Solutions for Regulated Industries

Key Takeaways: Powered by lumidawealth.com Capgemini has teamed up with Mistral AI and SAP to provide generative AI-powered solutions tailored for regulated industries. The collaboration leverages Mistral AI’s advanced...

Read more

OpenAI Expands to South Korea, Citing Strong AI Adoption and Market Potential

by Team Lumida
6 days ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

Key Takeaways: Powered by lumidawealth.com OpenAI has established a legal entity in South Korea and plans to open an office in Seoul in the coming months to support partnerships...

Read more

The “Best and Final” Job Offer Isn’t Always Final: How to Negotiate for More

by Team Lumida
1 week ago
The “Best and Final” Job Offer Isn’t Always Final: How to Negotiate for More

Key Takeaways: Only 31% of job seekers negotiated their offers recently, down from 49% last year, as companies increasingly present offers as “best and final.” Even when salaries...

Read more

DOJ Probes Google’s Deal with Character.AI for Potential Antitrust Violations

by Team Lumida
1 week ago
China Stimulus: Enough to Sway Markets?

Key Takeaways: The U.S. Department of Justice (DOJ) is investigating whether Google’s licensing agreement with Character.AI violates antitrust laws by circumventing formal government merger scrutiny. Google signed a...

Read more
Next Post
Solar Charging Station in the Parking Lot

Xpeng Charges Into Hong Kong with New EV Models

a view of a city with a lake and mountains in the background

China Unleashes $42B Rescue to Save Crumbling Property Sector

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Salesforce Q2 FY25 Earnings Highlights: Strong Growth Led by Integrating AI Solutions

Salesforce Eyes AI-Driven Growth Amid Slowing Core Business Expansion

February 26, 2025
a white square with a blue logo on it

Meta Taps Republican Joel Kaplan as Global Affairs Chief Ahead of Trump’s Return

January 3, 2025
person holding white and orange plastic bottle

AstraZeneca’s Breast Cancer Drug Camizestrant Shows Promising Late-Stage Trial Results

February 26, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018